On the stock market since 2021, it operates in the world of money and finance. It has 71 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
The biggest line carries real weight, but it doesn’t decide everything on its own.
No real growth (4% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades below its recent peak — about 15% off the top. A pullback, not a collapse.
Sales run at $16.5M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 7 buys and 5 sells. Management buying with its own money is usually read as a good sign.
It pays out $0.10 per share each year — regular cash for whoever holds the stock.
A loss of $4.7M against $16.5M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, GBNY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GBNY is a high-risk stock — not yet profitable, and its future rides on its product catching on.